NCI Studies Ivermectin for Cancer: RFK Jr. & Fringe Theories Fuel Research
- The National Cancer Institute (NCI) is undertaking a study to investigate the potential of ivermectin, an inexpensive anti-parasitic drug, as a cancer treatment.
- Ivermectin gained notoriety during the pandemic due to false assertions made by fringe medical groups regarding its ability to treat COVID-19.
- The NCI’s interest in ivermectin was publicly revealed during a January 30 event, as reported by KFF Health News and Ars Technica.
The National Cancer Institute (NCI) is undertaking a study to investigate the potential of ivermectin, an inexpensive anti-parasitic drug, as a cancer treatment. This move comes despite the lack of robust scientific evidence supporting its efficacy against cancer and follows years of unsubstantiated claims promoting ivermectin as a cure-all, including during the COVID-19 pandemic.
Ivermectin gained notoriety during the pandemic due to false assertions made by fringe medical groups regarding its ability to treat COVID-19. Large-scale clinical trials have definitively shown ivermectin to be ineffective against the virus. Now, the drug is being re-positioned by some as a potential cancer therapy.
The NCI’s interest in ivermectin was publicly revealed during a event, as reported by KFF Health News and Ars Technica. Anthony Letai, the director of the NCI, appointed by the Trump administration in , stated that the institute had initiated a preclinical study to examine the drug’s properties and its ability to kill cancer cells. “We’ll probably have those results in a few months,” Letai said.
While acknowledging the interest surrounding ivermectin, Letai cautioned against overblown expectations. “It’s not going to be a cure-all for cancer,” he stated. He further clarified that even if the preclinical studies reveal some anti-cancer properties, “it’s not a really strong signal.”
Ivermectin’s Potential Anticancer Properties: What the Research Shows
The renewed interest in ivermectin as a potential cancer treatment stems from preclinical research – studies conducted in laboratory settings and on animals – suggesting the drug may have antitumor effects. Research indicates ivermectin may inhibit cancer cell proliferation, metastasis (the spread of cancer), and angiogenesis (the formation of new blood vessels that feed tumors). These effects may be linked to ivermectin’s ability to regulate multiple signaling pathways within cancer cells, specifically through a protein called PAK1. A review published in Pharmacological Research in details these findings.
Further research, as highlighted in a report from Macmillan Cancer Support, suggests ivermectin might induce death in cancer cells and disrupt their internal communication systems. This review on ScienceDirect points to these potential mechanisms of action.
However, it’s crucial to understand the distinction between preclinical findings and clinical evidence. Preclinical studies provide a foundation for further investigation, but they do not guarantee the same results will be observed in humans.
The Gap Between Lab Results and Clinical Application
Currently, there is a significant lack of large-scale, randomized controlled trials – the gold standard in medical research – confirming ivermectin’s therapeutic benefits in humans with cancer. A review published in Current Oncology Reports in emphasizes this critical translational gap. While preclinical studies are promising, the absence of robust clinical data limits ivermectin’s utility in cancer treatment.
The review also highlights a concerning trend: observational studies and case reports indicate that self-medication with ivermectin, fueled by misinformation circulating on social media, can be harmful to oncology patients. This can lead to toxicity and potentially cause patients to forgo proven, evidence-based cancer therapies.
Responsible Communication and the Need for Rigorous Research
The current situation underscores the importance of responsible communication from healthcare providers. It is vital to counter misinformation and guide patients toward evidence-based interventions. The affordability of ivermectin may be appealing, particularly in resource-limited settings, but ethical concerns arise when unsubstantiated claims lead patients to abandon established treatments.
The NCI’s decision to pursue further research on ivermectin is not necessarily an endorsement of its efficacy. Rather, it reflects a commitment to exploring all potential avenues for cancer treatment. However, it is essential that this research is conducted rigorously and that the results are interpreted cautiously. The scientific community must prioritize large-scale clinical trials to bridge the gap between preclinical findings and practical clinical application.
Until such trials are completed, ivermectin should not be considered a standard treatment for cancer. Patients should always consult with their healthcare providers about appropriate and evidence-based cancer therapies.